EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor

Don B Sanders, Nicole Mayer-Hamblett, Margaret Rosenfeld, Deepika Polinieni, Elliott Dasenbrook, Rhonda Szczesniak, Elizabeth A Cromwell

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2024.07.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Don B Sanders und 6 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University School of Medicine, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We characterized people with cystic fibrosis (CF) ineligible by genotype (not age) for currently approved CFTR modulator therapy using data from the US CF Foundation Patient Registry (CFFPR). METHODS: We summarized clinical characteristics using CFFPR data from 2017 to 2022. Annual rate of change in percent predicted of forced expiratory volume in one second (ppFEV1) was estimated using generalized estimating equations. RESULTS: A total of 2,790 individuals with CF met inclusion criteria. In 2022, 12 % were less than 6 years old, 16 % were age 6-12 years, 18 % age 12-18 years and 54 % were ≥18 years. The proportion identified as White was 74 %, 17 % Black, and 26 % as Hispanic. The median (IQR) age at diagnosis was 1.2 (0.5, 9.1) months for children and 3.1 (0.3, 17.4) years for adults. Median (IQR) ppFEV1 among children was 91.9 (80.3; 102.4) and among adults, 74.3 (52.4; 90.4). Pancreatic enzymes were prescribed for 77.8 %. Population-level average (95 % CI) rates of decline in ppFEV1 among the pancreatic insufficient population was -1.5 per year (-1.8; -1.2) for ages 6 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesBenzodioxolesHumansUnited StatesChildAdolescentMaleFemaleAminophenolsAdultRegistriesYoung AdultDrug CombinationsCystic Fibrosis Transmembrane Conductance RegulatorChloride Channel AgonistsChild, PreschoolForced Expiratory VolumeIndolesPyridinesPyrazolesPyrrolidinesQuinolines

Stichwörter der Autor:innen

CFTR modulator ineligibleCystic fibrosis

Substanzen

QuinolonesAminophenolsivacaftorBenzodioxolesDrug CombinationsCystic Fibrosis Transmembrane Conductance RegulatorChloride Channel AgonistselexacaftortezacaftorIndoles

Autor:innen und Institutionen

  • Indiana University School of Medicine, Indianapolis, IN, United States.
  • Seattle Children's Hospital, Seattle, WA, United States; University of Washington, Seattle, WA, United States.
  • Seattle Children's Hospital, Seattle, WA, United States.
  • Washington University in St. Louis, St. Louis, MO, United States.
  • Cleveland Clinic, Cleveland, OH, United States.
  • Cincinnati Children's Hospital and the University of Cincinnati, Cincinnati, OH, United States.

Förderung

  • Cystic Fibrosis Foundation

Zitieren

APA

Sanders, D. B., Mayer-Hamblett, N., Rosenfeld, M., Polinieni, D., Dasenbrook, E., Szczesniak, R., & Cromwell, E. A. (2025). Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.07.015

Vancouver

Sanders DB, Mayer-Hamblett N, Rosenfeld M, Polinieni D, Dasenbrook E, Szczesniak R, et al. Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.07.015

BibTeX
@article{Sanders2025,
  author = {Sanders, Don B and Mayer-Hamblett, Nicole and Rosenfeld, Margaret and Polinieni, Deepika and Dasenbrook, Elliott and Szczesniak, Rhonda and Cromwell, Elizabeth A},
  title = {Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2024.07.015}
}
Kostenlos starten →